129 related articles for article (PubMed ID: 15253862)
21. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis.
Pittler MH; Ernst E
J Clin Psychopharmacol; 2000 Feb; 20(1):84-9. PubMed ID: 10653213
[TBL] [Abstract][Full Text] [Related]
22. Short-term open-label chamomile (Matricaria chamomilla L.) therapy of moderate to severe generalized anxiety disorder.
Keefe JR; Mao JJ; Soeller I; Li QS; Amsterdam JD
Phytomedicine; 2016 Dec; 23(14):1699-1705. PubMed ID: 27912871
[TBL] [Abstract][Full Text] [Related]
23. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum.
Sarris J; Kavanagh DJ; Byrne G; Bone KM; Adams J; Deed G
Psychopharmacology (Berl); 2009 Aug; 205(3):399-407. PubMed ID: 19430766
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic potential of kava in the treatment of anxiety disorders.
Singh YN; Singh NN
CNS Drugs; 2002; 16(11):731-43. PubMed ID: 12383029
[TBL] [Abstract][Full Text] [Related]
25. Kava kava in the treatment of generalized anxiety disorder, simple phobia and specific social phobia.
Boerner RJ
Phytother Res; 2001 Nov; 15(7):646-7. PubMed ID: 11746854
[TBL] [Abstract][Full Text] [Related]
26. St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial.
Sarris J; Kavanagh DJ; Deed G; Bone KM
Hum Psychopharmacol; 2009 Jan; 24(1):41-8. PubMed ID: 19090505
[TBL] [Abstract][Full Text] [Related]
27. Kava for the treatment of generalized anxiety disorder RCT: analysis of adverse reactions, liver function, addiction, and sexual effects.
Sarris J; Stough C; Teschke R; Wahid ZT; Bousman CA; Murray G; Savage KM; Mouatt P; Ng C; Schweitzer I
Phytother Res; 2013 Nov; 27(11):1723-8. PubMed ID: 23348842
[TBL] [Abstract][Full Text] [Related]
28. Kava: a comprehensive review of efficacy, safety, and psychopharmacology.
Sarris J; LaPorte E; Schweitzer I
Aust N Z J Psychiatry; 2011 Jan; 45(1):27-35. PubMed ID: 21073405
[TBL] [Abstract][Full Text] [Related]
29. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
30. Neuroimaging Insights: Kava's (
Savage K; Sarris J; Hughes M; Bousman CA; Rossell S; Scholey A; Stough C; Suo C
Nutrients; 2023 Oct; 15(21):. PubMed ID: 37960239
[TBL] [Abstract][Full Text] [Related]
31. The comparative clinical study of efficacy of Gamisoyo-San (Jiaweixiaoyaosan) on generalized anxiety disorder according to differently manufactured preparations: multicenter, randomized, double blind, placebo controlled trial.
Park DM; Kim SH; Park YC; Kang WC; Lee SR; Jung IC
J Ethnopharmacol; 2014 Dec; 158 Pt A():11-7. PubMed ID: 25456420
[TBL] [Abstract][Full Text] [Related]
32. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia.
Jacobs BP; Bent S; Tice JA; Blackwell T; Cummings SR
Medicine (Baltimore); 2005 Jul; 84(4):197-207. PubMed ID: 16010204
[TBL] [Abstract][Full Text] [Related]
33. How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies.
Kasper S; Brasser M; Schweizer E; Lyndon G; Prieto R
Eur Neuropsychopharmacol; 2014 Jan; 24(1):125-32. PubMed ID: 24290532
[TBL] [Abstract][Full Text] [Related]
34. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Sheehan DV; McElroy SL; Harnett-Sheehan K; Keck PE; Janavs J; Rogers J; Gonzalez R; Shivakumar G; Suppes T
J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
[TBL] [Abstract][Full Text] [Related]
35. Kava (Piper methysticum).
J Soc Integr Oncol; 2009; 7(4):170-2. PubMed ID: 19883532
[No Abstract] [Full Text] [Related]
36. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.
Pollack MH; Tiller J; Xie F; Trivedi MH
J Clin Psychopharmacol; 2008 Jun; 28(3):308-16. PubMed ID: 18480688
[TBL] [Abstract][Full Text] [Related]
37. Kava in generalized anxiety disorder: three placebo-controlled trials.
Connor KM; Payne V; Davidson JR
Int Clin Psychopharmacol; 2006 Sep; 21(5):249-53. PubMed ID: 16877894
[TBL] [Abstract][Full Text] [Related]
38. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
Rickels K; Pollack MH; Feltner DE; Lydiard RB; Zimbroff DL; Bielski RJ; Tobias K; Brock JD; Zornberg GL; Pande AC
Arch Gen Psychiatry; 2005 Sep; 62(9):1022-30. PubMed ID: 16143734
[TBL] [Abstract][Full Text] [Related]
39. Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial.
Lehrl S
J Affect Disord; 2004 Feb; 78(2):101-10. PubMed ID: 14706720
[TBL] [Abstract][Full Text] [Related]
40. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
Cutler NR; Sramek JJ; Keppel Hesselink JM; Krol A; Roeschen J; Rickels K; Schweizer E
J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
